Strong associations between TNBC and BRCA mutation status have been reported: 70-90% and 16-23% of breast tumors in BRCA1 and BRCA2 mutation carriers are TNBC [11]; however, germline mutations in BRCA1 and BRCA2 only account for 15.4% of patients with TNBC [13], and the prevalence of BRCA1 and BRCA2 mutations is lower in African American women (20.4%) with TNBC compared to European American women (33.3%) [14]. The gene discussed is BRCA1; the disease is breast neoplasm.